The GEO Group (GEO) Q4 2025 earnings review
Record Wins Drive Growth, But Margins Compress
GEO Group closed 2025 with strong momentum, delivering 16% YoY revenue growth in Q4 driven by record contract wins and ICE capacity expansion (20k to 26k beds). While the topline story is robust—with FY26 revenue guided to hit ~$3.0B—profitability is lagging. Adjusted EBITDA margins are implied to compress in FY26, and Q1 guidance forecasts a sequential dip in both revenue and earnings due to contract transitions and seasonality. The $38M litigation reserve for the Nwauzor case remains a key overhang.
🐂 Bull Case
2025 was the best year for new business in company history, securing $520M in annualized revenue. ICE capacity expanded by 30% (6,000 beds), and 6,000 idle beds remain available for future activation.
Deleveraging targets are being met (Net Debt ~$1.5B), enabling a shift to shareholder returns. GEO repurchased $49M of stock in Q4 alone, with over $400M remaining on the authorization.
🐻 Bear Case
Despite double-digit revenue growth, FY26 EBITDA guidance ($490-510M) implies margins dropping to ~16.7% from 17.6% in FY25. Start-up costs and mix shifts are eating into operating leverage.
A $38.2M non-cash reserve was booked for the Nwauzor v. GEO case (state minimum wage for detainees). An adverse Supreme Court ruling could have broader financial implications for the industry.
⚖️ Verdict: 🟢
Bullish. The revenue ramp is undeniable and backed by signed contracts. While margin compression and the Q1 air pocket are annoying, the volume growth and idle capacity upside outweigh the near-term friction.
Key Themes
ICE Capacity Supercycle
The core growth engine is firing on all cylinders. GEO activated 6,000 beds in 2025, increasing ICE capacity to 26,000. New facilities like North Lake and D. Ray James are ramping up. Management explicitly flagged 6,000 *more* high-security idle beds as 'additional growth opportunities' for 2026.
Litigation Overhang: Nwauzor Case
The company booked a $38.2M reserve related to the Nwauzor v. GEO case, which claims detainees in voluntary work programs are entitled to state minimum wages. The 9th Circuit ruled against GEO; the case is appealed to the Supreme Court. This is a significant tail risk that could impact the entire private detention business model if upheld.
Q1 2026 'Air Pocket'
Momentum hits a speed bump in Q1 2026. Guidance calls for revenue of $680-$690M and EBITDA of $107-$112M, both down sequentially from Q4. Management cites front-loaded payroll taxes and a revenue gap from the 'Skip Tracing' contract transition. This interrupts the sequential growth trend established throughout 2025.
Deleveraging Unlocks Buybacks
The balance sheet transformation is largely complete. Net debt stands at ~$1.5B (down from highs), and the company bought back 2.97M shares in Q4 ($49M). With the Lawton facility sale proceeds banked and strong cash flow, GEO has shifted from survival mode to capital return mode.
Electronic Monitoring Evolution
The segment is evolving beyond simple ankle monitors. GEO secured a new 'Skip Tracing' contract (tracking non-detained individuals) and renewed the ISAP contract. While the ISAP renewal came with a 'financial reset' (lower pricing) in Q3, the volume upside from the 8-18 million non-detained docket remains a massive, albeit delayed, call option.
Other KPIs
Accelerating. Up 16.7% YoY from $108.0M in 24Q4. However, margin was 17.8%, effectively flat vs prior year, indicating that operating leverage is being offset by startup costs and mix shifts.
Accelerating. Nearly doubled from $18.2M in 24Q4. EPS of $0.25 beat the year-ago $0.13 decisively. Driven by lower interest expense (deleveraging) and higher operating income.
Stable/Improving. Down significantly from prior years due to the Lawton facility sale ($312M) and organic repayment. Leverage is now ~3.0x, well within the comfort zone to sustain buybacks.
Guidance
Accelerating. The midpoint ($3.0B) implies ~14% growth over FY25's $2.63B. This reflects the full-year run-rate of the 2025 contract wins. This is a continuation of the strong momentum seen in 25Q4.
Decelerating (Growth Rate). The midpoint ($500M) implies ~7.7% growth vs FY25's $464M. This is slower than revenue growth, implying margin compression (approx. 16.7% margin vs 17.6% in FY25).
Reversing. Down sequentially from $707.7M in 25Q4. Management blames the gap in Skip Tracing revenue and fewer days in the quarter. Still up ~13% YoY.
Reversing. Down markedly from $126M in 25Q4. Attributed to front-loaded payroll taxes (typical Q1 seasonality) and the contract transition gap.
Key Questions
Margin Compression Drivers
FY26 guidance implies EBITDA margins dropping to ~16.7% from 17.6% in FY25. Is this structural due to the new ISAP contract pricing, or temporary due to startup costs for the 6,000 new beds?
Litigation Risk Specifics
With the $38M reserve booked, what is the range of potential outcomes if the Supreme Court refuses to hear the Nwauzor case? Does this open the door to lookalike claims in other states?
Skip Tracing Gap
Can you quantify the revenue impact of the 'Skip Tracing' transition in Q1? When does the new two-year contract fully ramp to offset this gap?
Idle Bed Activation Pace
You have 6,000 high-security idle beds remaining. Are active negotiations underway for these, and are they included in the high-end of the FY26 revenue guidance ($3.1B)?